{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T16:20:34Z","timestamp":1783527634257,"version":"3.55.0"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2026,5,30]],"date-time":"2026-05-30T00:00:00Z","timestamp":1780099200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,5,30]],"date-time":"2026-05-30T00:00:00Z","timestamp":1780099200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Rheumatol Int"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Retroperitoneal fibrosis (RPF) is a rare fibro-inflammatory disease frequently complicated by ureteral obstruction and renal impairment. Due to its rarity, heterogeneous clinical course, and the absence of standardized treatment guidelines, optimal immunosuppressive management of RPF remains uncertain. This study aimed to evaluate the real-world effectiveness and safety of different immunosuppressive treatment strategies in patients with RPF. A retrospective, single-center observational study was conducted including patients with idiopathic or immune-mediated RPF treated between 2010 and 2025. Patients were grouped according to treatment strategy: intensive intravenous therapy with cyclophosphamide or rituximab, or less intensive oral immunosuppressive therapy including methotrexate, mycophenolate mofetil or azathioprine. Treatment effectiveness was assessed using a composite endpoint incorporating clinical, laboratory and radiological response. Secondary outcomes included renal function, relapse, treatment safety, and glucocorticoid exposure. Twenty-nine patients were included in the analysis, of whom 11 received intensive therapy and 18 were treated with less intensive oral immunosuppressive regimens. Overall treatment effectiveness was achieved in 68% of evaluable patients and did not differ significantly between groups (OR 2.67, 95% CI 0.41\u201317.17). Clinical, laboratory, and radiological responses did not differ significantly between treatment groups. Hydronephrosis resolved in 75% of affected patients. Median serum creatinine levels improved during follow-up in both treatment groups, without significant intergroup differences at last observation (1.20\u00a0mg\/dL [1.10\u20131.30] vs. 1.20\u00a0mg\/dL [0.80\u20131.40]). The median relative reduction in periaortic mass thickness was 41.2% (24.45\u201353.95). No significant differences in overall safety outcomes were observed. In this real-world cohort of patients with RPF, intensive intravenous immunosuppressive regimens were not associated with superior treatment effectiveness compared with less intensive oral therapies. These findings support an individualized approach to treatment selection in RPF, taking disease severity, renal involvement and patient-specific factors into account. Prospective studies in larger cohorts are needed to further define optimal long-term management strategies for this rare disease.<\/jats:p>","DOI":"10.1007\/s00296-026-06166-5","type":"journal-article","created":{"date-parts":[[2026,5,30]],"date-time":"2026-05-30T03:28:36Z","timestamp":1780111716000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Comparable effectiveness of intensive intravenous and less intensive immunosuppressive treatment in retroperitoneal fibrosis: a retrospective real-world cohort study"],"prefix":"10.1007","volume":"46","author":[{"ORCID":"https:\/\/orcid.org\/0009-0005-2699-6103","authenticated-orcid":false,"given":"Adrianna","family":"Niksi\u0144ska","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4214-2982","authenticated-orcid":false,"given":"Robert","family":"Kruszewski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-8163-4265","authenticated-orcid":false,"given":"Micha\u0142","family":"W\u0105sik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-1533-8210","authenticated-orcid":false,"given":"Marta","family":"Kania-Pud\u0142o","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6311-0475","authenticated-orcid":false,"given":"Bart\u0142omiej","family":"Kisiel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3925-8813","authenticated-orcid":false,"given":"Ewa","family":"Malczuk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-9006-3604","authenticated-orcid":false,"given":"Jerzy","family":"Koblowski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7750-2901","authenticated-orcid":false,"given":"Witold","family":"T\u0142ustochowicz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,30]]},"reference":[{"key":"6166_CR1","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1007\/s11926-020-00966-9","volume":"23","author":"P Fenaroli","year":"2021","unstructured":"Fenaroli P, Maritati F, Vaglio A (2021) Into clinical practice: diagnosis and therapy of retroperitoneal fibrosis. Curr Rheumatol Rep 23:18. https:\/\/doi.org\/10.1007\/s11926-020-00966-9","journal-title":"Curr Rheumatol Rep"},{"key":"6166_CR2","doi-asserted-by":"publisher","first-page":"1880","DOI":"10.1681\/ASN.2015101110","volume":"27","author":"A Vaglio","year":"2016","unstructured":"Vaglio A, Maritati F (2016) Idiopathic retroperitoneal fibrosis. J Am Soc Nephrol 27:1880\u20131889. https:\/\/doi.org\/10.1681\/ASN.2015101110","journal-title":"J Am Soc Nephrol"},{"key":"6166_CR3","doi-asserted-by":"publisher","first-page":"742","DOI":"10.1038\/sj.ki.5002427","volume":"72","author":"D Corradi","year":"2007","unstructured":"Corradi D, Maestri R, Palmisano A, Bosio S, Greco P, Manenti L et al (2007) Idiopathic retroperitoneal fibrosis: clinicopathologic features and differential diagnosis. Kidney Int 72:742\u2013753. https:\/\/doi.org\/10.1038\/sj.ki.5002427","journal-title":"Kidney Int"},{"key":"6166_CR4","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1111\/iju.14218","volume":"27","author":"T Tanaka","year":"2020","unstructured":"Tanaka T, Masumori N (2020) Current approach to diagnosis and management of retroperitoneal fibrosis. Int J Urol 27:387\u2013394. https:\/\/doi.org\/10.1111\/iju.14218","journal-title":"Int J Urol"},{"key":"6166_CR5","doi-asserted-by":"publisher","first-page":"1258","DOI":"10.1007\/s00259-025-07479-6","volume":"53","author":"C Bayerl","year":"2026","unstructured":"Bayerl C, Kaufmann J, Metzger G, Rogasch JM, Amthauer H, Schatka I et al (2026) [18F]FDG PET\/CT for treatment monitoring and prediction of progression in retroperitoneal fibrosis. Eur J Nucl Med Mol Imaging 53:1258\u20131269. https:\/\/doi.org\/10.1007\/s00259-025-07479-6","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"6166_CR6","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1016\/j.ejim.2019.01.019","volume":"62","author":"G Morin","year":"2019","unstructured":"Morin G, Mageau A, Benali K, Bertinchamp R, Piekarski E, Raimbourg Q et al (2019) Persistent FDG\/PET CT uptake in idiopathic retroperitoneal fibrosis helps identifying patients at a higher risk for relapse. Eur J Intern Med 62:67\u201371. https:\/\/doi.org\/10.1016\/j.ejim.2019.01.019","journal-title":"Eur J Intern Med"},{"key":"6166_CR7","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1053\/j.ajkd.2007.02.268","volume":"49","author":"EFH van Bommel","year":"2007","unstructured":"van Bommel EFH, Siemes C, Hak LE, van der Veer SJ, Hendriksz TR (2007) Long-term renal and patient outcome in idiopathic retroperitoneal fibrosis treated with prednisone. Am J Kidney Dis 49:615\u2013625. https:\/\/doi.org\/10.1053\/j.ajkd.2007.02.268","journal-title":"Am J Kidney Dis"},{"key":"6166_CR8","doi-asserted-by":"publisher","first-page":"c213","DOI":"10.1159\/000119715","volume":"108","author":"AC Fry","year":"2008","unstructured":"Fry AC, Singh S, Gunda SS, Boustead GB, Hanbury DC, McNicholas TA et al (2008) Successful use of steroids and ureteric stents in 24 patients with idiopathic retroperitoneal fibrosis: a retrospective study. Nephron Clin Pract 108:c213\u2013220. https:\/\/doi.org\/10.1159\/000119715","journal-title":"Nephron Clin Pract"},{"key":"6166_CR9","first-page":"283","volume":"123","author":"PJ Scheel","year":"2012","unstructured":"Scheel PJ, Sozio SM, Feeley N (2012) Medical management of retroperitoneal fibrosis. Trans Am Clin Climatol Assoc 123:283\u2013290","journal-title":"Trans Am Clin Climatol Assoc"},{"key":"6166_CR10","doi-asserted-by":"publisher","first-page":"34","DOI":"10.14712\/23362936.2016.3","volume":"117","author":"M Pr\u016fcha","year":"2016","unstructured":"Pr\u016fcha M, Kolombo I, \u0160t\u00e1dler P (2016) Combination of steroids and azathioprine in the treatment of Ormond\u2019s disease-a single centre retrospective analysis. Prague Med Rep 117:34\u201341. https:\/\/doi.org\/10.14712\/23362936.2016.3","journal-title":"Prague Med Rep"},{"key":"6166_CR11","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1016\/j.amjmed.2003.08.033","volume":"116","author":"R Marcolongo","year":"2004","unstructured":"Marcolongo R, Tavolini IM, Laveder F, Busa M, Noventa F, Bassi P et al (2004) Immunosuppressive therapy for idiopathic retroperitoneal fibrosis: a retrospective analysis of 26 cases. Am J Med 116:194\u2013197. https:\/\/doi.org\/10.1016\/j.amjmed.2003.08.033","journal-title":"Am J Med"},{"key":"6166_CR12","doi-asserted-by":"publisher","first-page":"1544","DOI":"10.55563\/clinexprheumatol\/atxzl5","volume":"41","author":"F Vianello","year":"2023","unstructured":"Vianello F, Romano Gargarella L, Cinetto F, Scarpa R, Ceccato J, Marcolongo R (2023) Usefulness of methotrexate in relapsing idiopathic retroperitoneal fibrosis. Clin Exp Rheumatol 41:1544\u20131547. https:\/\/doi.org\/10.55563\/clinexprheumatol\/atxzl5","journal-title":"Clin Exp Rheumatol"},{"key":"6166_CR13","doi-asserted-by":"publisher","first-page":"1584","DOI":"10.1136\/annrheumdis-2013-203267","volume":"72","author":"F Alberici","year":"2013","unstructured":"Alberici F, Palmisano A, Urban ML, Maritati F, Oliva E, Manenti L et al (2013) Methotrexate plus prednisone in patients with relapsing idiopathic retroperitoneal fibrosis. Ann Rheum Dis 72:1584\u20131586. https:\/\/doi.org\/10.1136\/annrheumdis-2013-203267","journal-title":"Ann Rheum Dis"},{"key":"6166_CR14","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1136\/annrheumdis-2011-200148","volume":"71","author":"M Binder","year":"2012","unstructured":"Binder M, Uhl M, Wiech T, Thiel J, Sass JO, Walker UA et al (2012) Cyclophosphamide is a highly effective and safe induction therapy in chronic periaortitis: a long-term follow-up of 35 patients with chronic periaortitis. Ann Rheum Dis 71:311\u2013312. https:\/\/doi.org\/10.1136\/annrheumdis-2011-200148","journal-title":"Ann Rheum Dis"},{"key":"6166_CR15","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1016\/S0140-6736(11)60934-3","volume":"378","author":"A Vaglio","year":"2011","unstructured":"Vaglio A, Palmisano A, Alberici F, Maggiore U, Ferretti S, Cobelli R et al (2011) Prednisone versus tamoxifen in patients with idiopathic retroperitoneal fibrosis: an open-label randomised controlled trial. Lancet 378:338\u2013346. https:\/\/doi.org\/10.1016\/S0140-6736(11)60934-3","journal-title":"Lancet"},{"key":"6166_CR16","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1093\/ckj\/sfv148","volume":"9","author":"FE van der Bilt","year":"2016","unstructured":"van der Bilt FE, Hendriksz TR, van der Meijden WAG, Brilman LG, van Bommel EFH (2016) Outcome in patients with idiopathic retroperitoneal fibrosis treated with corticosteroid or tamoxifen monotherapy. Clin Kidney J 9:184\u2013191. https:\/\/doi.org\/10.1093\/ckj\/sfv148","journal-title":"Clin Kidney J"},{"key":"6166_CR17","doi-asserted-by":"publisher","first-page":"1714","DOI":"10.1111\/1756-185X.14798","volume":"26","author":"M Oztas","year":"2023","unstructured":"Oztas M, Altun I, Ayla AY, Cerme E, Demirdag C, Asa S et al (2023) Rituximab in the management of retroperitoneal fibrosis: a single tertiary rheumatology care center experience. Int J Rheum Dis 26:1714\u20131721. https:\/\/doi.org\/10.1111\/1756-185X.14798","journal-title":"Int J Rheum Dis"},{"key":"6166_CR18","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1186\/s41927-020-00140-9","volume":"4","author":"V Boyeva","year":"2020","unstructured":"Boyeva V, Alabsi H, Seidman MA, Paterson R, Kur J, Chen LY et al (2020) Use of rituximab in idiopathic retroperitoneal fibrosis. BMC Rheumatol 4:40. https:\/\/doi.org\/10.1186\/s41927-020-00140-9","journal-title":"BMC Rheumatol"},{"key":"6166_CR19","doi-asserted-by":"publisher","first-page":"e003007","DOI":"10.1136\/rmdopen-2023-003007","volume":"9","author":"A Wang","year":"2023","unstructured":"Wang A, Peng L, Zhou J, Liu Z, Lu H, Peng Y et al (2023) Pilot study of tocilizumab monotherapy for active chronic periaortitis. RMD Open 9:e003007. https:\/\/doi.org\/10.1136\/rmdopen-2023-003007","journal-title":"RMD Open"},{"key":"6166_CR20","doi-asserted-by":"publisher","first-page":"e12631","DOI":"10.1097\/MD.0000000000012631","volume":"97","author":"R Wallwork","year":"2018","unstructured":"Wallwork R, Wallace Z, Perugino C, Sharma A, Stone JH (2018) Rituximab for idiopathic and IgG4-related retroperitoneal fibrosis. Med (Baltim) 97:e12631. https:\/\/doi.org\/10.1097\/MD.0000000000012631","journal-title":"Med (Baltim)"},{"key":"6166_CR21","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1186\/s41927-024-00445-z","volume":"9","author":"A Steimer","year":"2025","unstructured":"Steimer A, Becker MO (2025) Treatment approaches for idiopathic retroperitoneal fibrosis: a systematic review with meta-analysis. BMC Rheumatol 9:12. https:\/\/doi.org\/10.1186\/s41927-024-00445-z","journal-title":"BMC Rheumatol"},{"key":"6166_CR22","doi-asserted-by":"publisher","DOI":"10.1186\/s40001-026-03856-5","author":"T Zheng","year":"2026","unstructured":"Zheng T, Wu Z, Ding Y, Pan C, Shi Y, Gao H (2026) Glucocorticoid monotherapy vs. immunosuppressant-combined therapy in retroperitoneal fibrosis: clinical evidence and mechanistic insights from bioinformatics. Eur J Med Res. https:\/\/doi.org\/10.1186\/s40001-026-03856-5","journal-title":"Eur J Med Res"},{"key":"6166_CR23","doi-asserted-by":"publisher","first-page":"103487","DOI":"10.1016\/j.jaut.2025.103487","volume":"157","author":"F Peyronel","year":"2025","unstructured":"Peyronel F, Palmisano A, Maritati F, Alberici F, Urban ML, Gianfreda D et al (2025) Methotrexate and low-dose prednisone in idiopathic retroperitoneal fibrosis: a randomised clinical trial. J Autoimmun 157:103487. https:\/\/doi.org\/10.1016\/j.jaut.2025.103487","journal-title":"J Autoimmun"},{"key":"6166_CR24","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1007\/s00296-025-06065-1","volume":"13","author":"A Hammitzsch","year":"2026","unstructured":"Hammitzsch A, Ferraro N, Bachmann Q, Heemann U, Moog P (2026) Long-term treatment patterns and outcomes in IgG4-related disease \u2013 a retrospective single-center cohort study focusing on rituximab. Rheumatol Int 13:46:33. https:\/\/doi.org\/10.1007\/s00296-025-06065-1","journal-title":"Rheumatol Int"},{"key":"6166_CR25","doi-asserted-by":"publisher","DOI":"10.1093\/rap\/rkae020","author":"Z Wallace","year":"2024","unstructured":"Wallace Z, Katz G, Hernandez-Barco YG, Baker MC (2024) Current and future advances in practice: IgG4-related disease. Rhematol Adv Pract. https:\/\/doi.org\/10.1093\/rap\/rkae020. 10;8","journal-title":"Rhematol Adv Pract"},{"key":"6166_CR26","doi-asserted-by":"publisher","first-page":"6774","DOI":"10.1093\/rap\/rkae020","volume":"25","author":"A Gonzalez-Garcia","year":"2025","unstructured":"Gonzalez-Garcia A, Starita-Fajardo G, Lopez DL, Alcolea MP, Lopez-Paraja M, Pena-Rodriguez M et al (2025) New developments in the treatment of IgG4-related disease: a comprehensive clinical approach. J Clin Med 25:14:6774. https:\/\/doi.org\/10.1093\/rap\/rkae020","journal-title":"J Clin Med"},{"key":"6166_CR27","doi-asserted-by":"publisher","first-page":"265","DOI":"10.2147\/POR.S562743","volume":"16","author":"S Huang","year":"2025","unstructured":"Huang S, Wang A, Jia Y, Han W, Zhao N, Wang T et al (2025) Relapse predictors of idiopathic retroperitoneal fibrosis: a long-term cohort study. Pragmatic Obs Res 16:265\u2013277. https:\/\/doi.org\/10.2147\/POR.S562743","journal-title":"Pragmatic Obs Res"},{"key":"6166_CR28","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1111\/iju.12234","volume":"21","author":"S Mertens","year":"2014","unstructured":"Mertens S, Zeegers AGM, Wertheimer PA, Hendriksz TR, van Bommel EFH (2014) Efficacy and complications of urinary drainage procedures in idiopathic retroperitoneal fibrosis complicated by extrinsic ureteral obstruction. Int J Urol 21:283\u2013288. https:\/\/doi.org\/10.1111\/iju.12234","journal-title":"Int J Urol"},{"key":"6166_CR29","doi-asserted-by":"publisher","first-page":"1665","DOI":"10.1007\/s00296-014-3002-6","volume":"34","author":"H Liu","year":"2014","unstructured":"Liu H, Zhang G, Niu Y, Jiang N, Xiao W (2014) Retroperitoneal fibrosis: a clinical and outcome analysis of 58 cases and review of literature. Rheumatol Int 34:1665\u20131670. https:\/\/doi.org\/10.1007\/s00296-014-3002-6","journal-title":"Rheumatol Int"}],"container-title":["Rheumatology International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00296-026-06166-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00296-026-06166-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00296-026-06166-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T15:39:22Z","timestamp":1783525162000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00296-026-06166-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,30]]},"references-count":29,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2026,6]]}},"alternative-id":["6166"],"URL":"https:\/\/doi.org\/10.1007\/s00296-026-06166-5","relation":{},"ISSN":["1437-160X"],"issn-type":[{"value":"1437-160X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,30]]},"assertion":[{"value":"9 March 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no conflicts of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The study protocol was reviewed by the Local Bioethics Committee (The Bioethics Committee of the Military Institute of Medicine- National Research Institute in Warsaw), which determined that formal ethical approval was not required due to the retrospective and non-interventional nature of the study (Resolution No. 64\/25 of 19 November 2025 regarding a scientific study not constituting a medical experiment, with registration No. KB\/59\/25. The study was conducted in accordance with the Declaration of Helsinki (2024 version).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Due to the retrospective design of the study, the requirement for informed consent was waived.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}},{"value":"AI-assisted tools were used exclusively for language editing purposes (OpenAI, GPT-5.5, March 2026). The authors are fully responsible for the study design, data analysis, and the content of the manuscript. No part of this report was copied or generated using AI tools.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"AI statement"}}],"article-number":"120"}}